Investigating receptor enzyme activity using time-scale analysis

Investigating receptor enzyme activity using time-scale analysis

For access to this article, please select a purchase option:

Buy article PDF
(plus tax if applicable)
Buy Knowledge Pack
10 articles for $120.00
(plus taxes if applicable)

IET members benefit from discounts to all IET publications and free access to E&T Magazine. If you are an IET member, log in to your account and the discounts will automatically be applied.

Learn more about IET membership 

Recommend Title Publication to library

You must fill out fields marked with: *

Librarian details
Your details
Why are you recommending this title?
Select reason:
IET Systems Biology — Recommend this title to your library

Thank you

Your recommendation has been sent to your librarian.

At early drug discovery, purified protein-based assays are often used to characterise compound potency. In the context of dose response, it is often perceived that a time-independent inhibitor is reversible and a time-dependent inhibitor is irreversible. The legitimacy of this argument is investigated using a simple kinetics model, where it is revealed by model-based analytical analysis and numerical studies that dose response of an irreversible inhibitor may appear time-independent under certain parametric conditions. Hence, the observation of time-independence cannot be used as sole evidence for identification of inhibitor reversibility. It has also been discussed how the synthesis and degradation of a target receptor affect drug inhibition in an in vitro cell-based assay setting. These processes may also influence dose response of an irreversible inhibitor in such a way that it appears time-independent under certain conditions. Furthermore, model-based steady-state analysis reveals the complexity nature of the drug–receptor process.


    1. 1)
      • 1. Sorger, P.K., Allerheiligen, S.R., Abernethy, D.R., et al: ‘Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms’. An NIH White Paper by the QSP Workshop Group, NIH, Bethesda, 2011, pp. 148.
    2. 2)
    3. 3)
    4. 4)
    5. 5)
    6. 6)
    7. 7)
    8. 8)
    9. 9)
      • 9. Orrell, D., Fernandez, E.: ‘Using predictive mathematical models to optimise the scheduling of anti-cancer drugs’, Innov. Pharm. Technol., 2010, 33, pp. 5862.
    10. 10)
    11. 11)
    12. 12)
    13. 13)
    14. 14)
    15. 15)
    16. 16)
      • 16. Strelow, J., Dewe, W., Iversen, P., et al: ‘Mechanism of action assays for enzymes’, 2004.
    17. 17)
    18. 18)
    19. 19)
    20. 20)
      • 20. Lauffenburger, D.A., Linderman, J.J.: ‘Receptors: models for binding, trafficking, and signaling’ (Oxford University Press, New York, 1993).
    21. 21)
      • 21. Hendriks, B.S., Opresko, L.K., Wiley, H.S., Lauffenburger, D.: ‘Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations quantitative analysis of HER2 overexpression effects’, Cancer Res., 2003, 63, (5), pp. 11301137.
    22. 22)

Related content

This is a required field
Please enter a valid email address